The identification of novel translocation partner genes involved in MLL rearrangements increases the chances of identifying novel possibilities for a targeted, molecular therapy. Concerted efforts by many research groups in collaboration with the Diagnostic Center of Acute Leukemia (DCAL) at Frankfurt University have made it possible to establish the MLL recombinome database.